SEC Filing Summary: BioSig Technologies, Inc. (BSGM)
Business Context and Reporting Period
This Form 8-K Current Report, dated April 18, 2023, details a private placement transaction by BioSig Technologies, Inc. (BSGM), a Delaware corporation trading on the NASDAQ Capital Market. The filing reports the entry into a Material Definitive Agreement and the unregistered sale of equity securities.
Key Financial Metrics and Transaction Details
The Company executed a private investment in public equity (PIPE) transaction, raising aggregate consideration of $945,001.40. The transaction structure included:
- Common Stock Sold: 792,454 shares at a purchase price of $1.1925 per share.
- Warrants Issued: Warrants to purchase up to 396,227 shares (50% of shares sold) at an exercise price of $1.13 per share.
- Warrant Terms: Exercisable six months post-issuance; expiration five and one-half years post-issuance.
- Placement Agent Compensation: A warrant to purchase 7,862 shares issued to Laidlaw & Company (UK) Ltd. at an exercise price of $1.13 per share with identical terms to the investor warrants.
The filing does not provide comparative revenue, profit, cash flow, margin, or debt metrics as this is a transaction-specific report rather than a periodic financial statement.
Material Changes and Unusual Items
The primary material change is the immediate increase in cash liquidity of approximately $945,000 and the dilution of existing shareholders through the issuance of 792,454 new shares and associated warrants. The transaction was conducted under Section 4(a)(2) and Regulation D exemptions from registration.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard representations and warranties typical for such transactions. The Company did not disclose the specific intended use of proceeds in this summary text.
Investor Verification Checklist
- Verify the exact number of shares outstanding post-transaction to assess dilution impact.
- Confirm the intended use of the $945,001.40 proceeds (e.g., working capital, debt repayment, R&D).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for restrictive covenants or registration rights.
- Monitor the six-month vesting period for the warrants to understand future potential dilution.
- Check subsequent filings for any changes in the Company's liquidity position or capital structure.